Please login to the form below

Not currently logged in


This page shows the latest Vertex news and features for those working in and with pharma, biotech and healthcare.

CRISPR gene-editing in cancer patients is safe, according to new study

CRISPR gene-editing in cancer patients is safe, according to new study

In November last year, Vertex and CRISPR Therapeutics revealed initial positive data from the first two patients treated with their investigational CRISPR/Cas9 gene-editing therapy CTX001. ... Unlike the Pennsylvania study, Vertex said that its CRISPR

Latest news

More from news
Approximately 56 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    Just Treatment is also urging the UK government to override Vertex’s patent via compulsory licensing or Crown Use Licence. ... Meticulous preparations. The supply of the generic drug comes from Argentinian pharma company Gador, whose Lucaftor is a copy

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi row explained The Orkambi row explained

    Is Vertex’s price reasonable? This is the million dollar question, so to speak. ... October 2016: Orkambi negotiations between Vertex, the UK government and the NHS get underway.

  • The Orkambi blame game The Orkambi blame game

    an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012. ... Vertex, at £850m a year, would go out of business in three to five years.

  • #OrkambiNow? #OrkambiNow?

    Looking to the future, Vertex and other companies will be developing more potent treatments, including gene therapies which could one day cure patients of this terrible disease. ... Fast forward to July 2018, and the row had escalated to the point where

More from intelligence
Approximately 6 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...